Medical Writing Patient-reported outcomes My First Medical Writing

Volume 27, Issue 4 - Patient-reported outcomes

My First Medical Writing

Abstract

After the debut of the first edition of this section, I was honoured to be contacted by many aspiring medical writers eager to contribute and to showcase their writing skills. Among them, Matías Rey-Carrizo did an
amazing job in translating a complex and controversial topic into an enjoyable read. Matías has a PhD in medicinal chemistry and an extensive experience in scientific publications. After his last postdoctoral stay in
Tokyo, he embarked on a medical writing journey as a freelancer at BCN Medical Writing. We hope you’ll enjoy reading this article as much as we enjoyed creating it. If you’re trying to get your foot in the door or
know someone who is, don’t hesitate and contact us!

References

  1. FDA News Release. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018 [cited 2018 Sep 19]. Available from Available from: https://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm611046.htm.
  2. Schultes RE, Klein WM, Plowman T, Lockwood TE. Cannabis: an example of taxonomic neglect. Bot Mus Lealf Harv Univ. 1974;23:337–67.
  3. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76(1-2):3–8.
  4. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006;105(1-2):1–25.
  5. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153–7.
  6. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc. 1964;86(8):1646–7.
  7. Devane WA, Dysarz FA, Johnson RM, Melvin S, Howlett C. Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Mol Pharmacol. 1988;34(5):605–13.
  8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.
  9. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science. 1992;258(10):1946–9.
  10. Elder JJ, Knoderer HM. Characterization of Dronabinol Usage in a Pediatric Oncology Population. J Pediatr Pharmacol Ther. 2015;20(6):462–7.
  11. Pergolizzi JV, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2017;79(3):467–77.
  12. Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18(8).
  13. Syed YY, McKeage K, Scott LJ. Delta-9- Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs. 2014;74(5):563–78.
  14. Kalant H. Medical use of cannabis: History and current status. Pain Res Manage. 2011;6(2):80–91.
  15. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A Random ized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. J Pain. 2008;9(6):506–21.
  16. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmaco - therapy. 2013;33(2):195–209.17.
  17. Scuderi C, De Filipis D, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders. Phytother Res. 2009;23:597–602.
  18. Devinsky O, Cross JH, FRCPCH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011–20.
  19. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.
  20. Rosemergy I, Adler J, Psirides A. Cannabidiol oil in the treatment of super refractory status epilepticus. A case report. Seizure. 2016;35:56–8.
  21. Shannon S, Opila-Lehman J. Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. Integr Med. 2015;14(6):31–5.
  22. Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018;35(4):e224–7.
  23. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016;20(4):108–11.

Search

Articles

Patient reported outcomes
President's Message
EMWA News
Measuring health outcomes: The foundation of contemporary healthcare decision-making
Measuring quality of life – theoretical background
Quality of life measures – an overview
Publication planning and patient-reported outcomes: Demonstrating value in a multi-stakeholder era
Patient-reported outcome measure translation: An overview
Systematic hospital collection of patient-reported outcome data via patient apps
The PROMIS of electronic patient-reported outcomes
Interview with Professor Matthias Rose on developing patient-reported outcomes and the PROMIS initiative
The UK pharmaceutical industry braces for Brexit, be it mild, severe, or doomsday
Awareness of medical writing as a profession and its career prospects
Estimands – closing the gap between study design and analysis
Protecting the rights of clinical trial patients through disclosure: The significance of plain language
News from the EMA
Regulatory Matters & Regulatory Public Disclosure
Medical Communications
Medical Devices
Journal Watch
In the Bookstores
Good Writing Practice
Getting Your Foot In The Door
My First Medical Writing
Out on Our Own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: